Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Epidermal Growth Factor Receptor
100%
Hepatocellular Carcinoma
100%
Tumor Progression
71%
5 (2,6 Dichlorobenzylsulfonyl) 3 [3,5 Dimethyl 4 [2 (1 Pyrrolidinylmethyl) 1 Pyrrolidinylcarbonyl] 1h Pyrrol 2 Ylmethylene] 1,3 Dihydro 2h Indol 2 One
42%
In Vitro
28%
Small Interfering RNA
28%
Short Hairpin RNA
28%
Scatter Factor
28%
Gene Expression Profiling
28%
Gefitinib
28%
Clinical Trial
14%
Neoplasm
14%
Combination Therapy
14%
Metastatic Carcinoma
14%
Cell Signaling Pathway
14%
Protein Expression
14%
Kinase
14%
Phosphatase
14%
Programmed Cell Death
14%
Cancer
14%
Akt Signaling
14%
Upregulation
14%
Protein Tyrosine Kinase
14%
Monotherapy
14%
Negative Feedback
14%
Oncogene
14%
Targeted Therapy
14%
Cell Viability
14%
Tumor Invasion
14%
Therapy Effect
14%
Tyrosine-Kinase Inhibitor
14%
Hepatocellular Carcinoma Cell Line
14%
Biochemistry, Genetics and Molecular Biology
Tumor Progression
100%
Epidermal Growth Factor Receptor
100%
Small Interfering RNA
40%
Gene Expression Profiling
40%
Small Hairpin RNA
40%
Hepatocyte Growth Factor
40%
Gefitinib
40%
Protein Expression
20%
In Vitro Study
20%
Cell Viability
20%
Akt Signaling
20%
Clinical Trial
20%
Oncogene
20%
Upregulation
20%
Receptor Tyrosine Kinase
20%
Product Inhibition
20%
Puromycin
20%
Tyrosine Kinase Inhibitor
20%
Survival Factor
20%
Receptor Affinity
20%
Phosphatase
20%
Programmed Cell Death
20%
Keyphrases
Survival Mechanism
100%
C-Met
100%
Hepatocellular Carcinoma
100%
Tumor Growth
22%
PHA665752
16%
RNAi Screen
11%
Gene Expression Profiling
11%
Short Hairpin RNA (shRNA)
11%
Hepatocyte Growth Factor
11%
Gefitinib
11%
MET Inhibitor
11%
High-throughput
5%
Clinical Trials
5%
Growth Kinetics
5%
Tumor
5%
Combination Therapy
5%
Tumor Metastasis
5%
Knockdown
5%
Phosphatase
5%
In Vitro Study
5%
Protein Expression
5%
Monotherapy
5%
Apoptosis
5%
Feedback Device
5%
Oncogene
5%
Cell Viability
5%
High-affinity Receptor
5%
Receptor Tyrosine Kinase
5%
Worse Prognosis
5%
Hepatocellular Carcinoma Cells
5%
Tumor Growth in Vivo
5%
Reduced Cell
5%
Therapeutic Regimen
5%
Negative Feedback
5%
Oncogenic Pathways
5%
Targeted Therapy
5%
PI3K-Akt Pathway
5%
Slow Growth
5%
Acquired Resistance
5%
Therapeutic Effect
5%
Tyrosine Kinase Inhibitor
5%
Growth in Vitro
5%
Tumor Invasion
5%
Stasis
5%
Survival Factor
5%
Hepatocellular Carcinoma Patients
5%
Survival Proteins
5%
MET Signaling
5%
EGFR Inhibition
5%
Pharmacology, Toxicology and Pharmaceutical Science
Epidermal Growth Factor Receptor
100%
Liver Cell Carcinoma
100%
Tumor Growth
62%
5 (2,6 Dichlorobenzylsulfonyl) 3 [3,5 Dimethyl 4 [2 (1 Pyrrolidinylmethyl) 1 Pyrrolidinylcarbonyl] 1h Pyrrol 2 Ylmethylene] 1,3 Dihydro 2h Indol 2 One
37%
Small Interfering RNA
25%
Short Hairpin RNA
25%
Scatter Factor
25%
Gefitinib
25%
Receptor
12%
Metastasis
12%
Neoplasm
12%
Clinical Trial
12%
Protein Kinase B
12%
Protein Tyrosine Kinase
12%
Combination Therapy
12%
Monotherapy
12%
Cell Viability
12%
Tumor Invasion
12%
Puromycin
12%
Therapeutic Effect
12%
Protein Tyrosine Kinase Inhibitor
12%
Survival Factor
12%
Phosphatase
12%